New York, NY (January 28, 2010) – Clinilabs, a contract research organization (CRO) specializing in early phase and specialty studies, is proud to announce that the Company has formed a collaboration with the Renal Research Institute, LLC (RRI), with headquarters in New York. This collaboration allows Clinilabs and the RRI to provide a high level of clinical drug development services to pharmaceutical and biotechnology companies. The collaboration includes Spectra Clinical Research, a division of Spectra Laboratories, the leading provider of renal-specific testing services in the United States.
Founded in 1997, Renal Research Institute, LLC is dedicated to advancing therapy options for dialysis patients to provide the highest caliber of care based on advanced clinical technology. RRI enhances the quality of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology. Spectra Clinical Research provides central clinical laboratory services for clinical trials, fusing the strength of a major laboratory facility with the responsiveness and dedication of a small, specialized team.
Dr. Gary K. Zammit, President & CEO of Clinilabs Inc., states, “Clinilabs is pleased announce its collaboration with the Renal Research Institute, LLC and Spectra Clinical Research. These alliances will enable us to complete studies in patients with renal impairment at our 48-bed phase 1 unit in New York; studies that are essential to early phase drug development. Our ability to bring three top organizations together in collaboration represents an important new offering for industry-sponsored research.”
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early phase and specialty clinical drug development services to industry. Our organization offers clients high quality, low cost solutions for single center and multicenter Phase I and II clinical trials. We also offer specialty drug development services in a variety of therapeutic areas, as well as a suite of electronic data capture and management tools under the brand Clinical InSite.™ For more information, please visit www.clinilabs.com.
About The Renal Research Institute (RRI)
Renal Research Institute, LLC (RRI) is dedicated to advancing therapy options for dialysis patients to provide the highest caliber of care based on advanced clinical technology. The Institute is committed to research and innovation that will lead to improved patient outcomes and quality of life. RRI strives for a compassionate approach to the patients it serves and to fulfill the needs and expectations of its customers. Through efficient application of new clinical therapies and technical innovations, RRI seeks to expand its network of facilities in collaboration with academic centers. RRI is dedicated to providing comprehensive renal services to providers, regional insurers, and managed care organizations with full recognition of the economic constraint under which they operate. Through its collaborative relationships with a network academic facilities, RRI is able to enhance the spectrum of comprehensive renal services by advancing peritoneal and hemodialysis therapies through clinical research and the application of practice guidelines and new technology. For more information, please visit www.renalresearch.com.
About Spectra Clinical Research
Spectra Clinical Research is a division of Spectra Laboratories, the leading provider of laboratory products and services in the renal industry. It is backed by nearly a decade of clinical trial expertise, and over 25 years of central laboratory services to the dialysis community, making Spectra an unmatched partner for pharmaceutical, biotechnology, research, government and academic organizations.
With headquarters in Rockleigh, New Jersey and a global partner network spanning six continents, Spectra’s capacity and expertise deliver success for a range of clinical investigations. The company offers flexibility, hands-on support, comprehensive services, capacity, 24/7 access, and global reach. For more information please visit www.spectraclinicalresearch.com.
